Oncology Overview Highlights
- 275+ community-based oncologists
- 75,000 New Cancer Patients Annually
- Trials easily accessible to a broad patient base
- Participation in industry-sponsored and investigator-initiated trials
- Phase I through III and Outcomes based trials
- Provide comprehensive patient care to a diverse patient population
Sarah Cannon Research Institute is a global strategic research organization focusing on advancing therapies and accelerating drug development. It is one of the largest clinical research programs, conducting community-based clinical trials in oncology and cardiology through affiliations with a network of physicians in the United States and United Kingdom. Additionally, Sarah Cannon offers management, regulatory and other research support services to drug development sponsors and strategic investigator sites.
Above all else, we are committed to the improvement of patient outcomes and advancement of medical science through innovation and quality execution of clinical research.
We strive to uphold an exceptional level of service delivered with the utmost compassion, personalization and professionalism.
We believe in an unwavering commitment to improving the treatment and lives of the patients we serve through high quality clinical research.
We adhere to rigorous standards in designing and conducting clinical trials.
We believe in the empowerment of and investment in our employees to perform with absolute integrity, honesty and reliability.
"Participation in a clinical trial is the first step in fighting cancer, not the last."
Jennifer Cole, VP, Clinical Operations
Renee Smith, Senior Director, Global Quality and Training
Amanda Bilbrey, Senior Director, Clinical Operations
Fran Palmieri, Director, Oncology Strategic Sites
Katherine Stark, Director, Early Phase Operations, TO-Nashville